PBYI Puma Biotechnology, Inc.: רווח למניה ב-12 החודשים האחרונים

Puma Biotechnology (PBYI) business relies on non-cyclical demand in the targeted therapy segment, where success depends on the expansion of indications for the drug Nerlynx. The inclusion of the drug Inertia in global treatment protocols ensures stable revenues. This chart of EPS value changes on GURU.Markets, reaching -36.40, is complemented by the implementation of cloud AI for accelerated biomedical data processing and the automation of clinical trials.

Year-over-year (TTM) EPS growth measures the percentage change in net income per share over twelve months, reflecting the efficiency of business capitalization. By analyzing the EPS YoY TTM trend, an investor sees the current value of -36.40, which allows for an assessment of the company's ability to scale profitability. This metric discounts the actual profitability of developments amid market volatility. The specific sovereign product cycle of Puma Biotechnology (PBYI) ensures the stability of this indicator regardless of global macroeconomic fluctuations.